Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Smithkline Beecham confounds the doubters: while Glaxo and Wellcome hog the limelight, SmithKline Beecham (SB) is quietly demonstrating that there is life after a major patent expiry

Article Abstract:

SmithKline Beecham's sales of Tagamet fell by 28% in 1994, to 484 million pounds sterling, however the decline was offset by increases in newer products, such as Paxil, an anti-depressant. Following the appointment of Jan Leschly as chief executive, the company announced the purchase of Diversified Pharmaceuticals Services, a drug wholesaler, and later it purchased Sterling's OTC business. It also sold its animal healthcare division.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
SmithKline Beecham Corp. (Philadelphia, Pennsylvania)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Tough battle for AAH: German wholesaler Gehe's move on AAH could be hard for the group to resist

Article Abstract:

Gehe of Germany, a major pharmaceuticals wholesaler, has made a hostile bid for AAH, a drugs distributor and environmental services group, which would allow it to enter the UK and Irish markets. AAH has a poor track record including two profit warnings and Gehe would have to invest in automated warehouse stock control to prevent AAH's margin decline.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
Pharmaceutical industry, Mergers, acquisitions and divestments, Gehe AG, AAH Holdings PLC

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Peptide Therapeutics

Article Abstract:

Peptide Therapeutics develops vaccines, and there are risks involved, despite a promising pipeline of products.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
Biological products exc. diagnostic, Vaccines for Human Use, Peptide Therapeutics, Vaccines industry, Biological products industry, Vaccines

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Management, Drugs
Similar abstracts:
  • Abstracts: Report of the Committee on the financial aspects of corporate governance: the code of best practice. Paying the piper
  • Abstracts: Frederick Cooper: over the rainbow. Jourdan presses on: the recession left scars at Thomas Jourdan, but the sale of the loss-making fitted kitchen operation and hopes for increased DIY business from Sainsbury's Homebase suggest a healthy recovery
  • Abstracts: A capital quandary: treasurers face some tough choices as they try to put cash flow to its most efficient use
  • Abstracts: A journey through liquidity management. Rewarding service with loyalty. New equity listings
  • Abstracts: An exploratory survey of rural accounting practitioners: accounting for sustainability. Accounting for macro-social impacts: a new research agenda
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.